Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)xCD3 bispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results of a phase 1, first-in-human study
Por:
Van De Donk, NWCJ, Krishnan, A, Oriol, A, Berdeja, JG, Rodriguez-Otero, P, Askari, E, Mateos, MV, Minnema, MC, Costa, L, Verona, R, Girgis, S, Prior, T, Hilder, B, Russell, J, Goldberg, J and Chari, A
Publicada:
1 oct 2021
Resumen:
Filiaciones:
Van De Donk, NWCJ:
Vrije Univ Amsterdam Med Ctr, Amsterdam Univ Med Ctr, Amsterdam, Netherlands
Krishnan, A:
City Hope Comprehens Canc Ctr, Duarte, CA USA
:
Hosp Badalona Germans Trias & Pujol, Inst Recerca Leucemia Josep Carreras, Barcelona, Spain
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain
Berdeja, JG:
Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA
Rodriguez-Otero, P:
CIBERONC, IDISNA, CIMA, Clin Univ Navarra, Pamplona, Spain
Askari, E:
Hosp Univ Fdn Jimenez Diaz, Madrid, Spain
Mateos, MV:
Univ Hosp Salamanca, Inst Canc Mol & Cellular Biol, Salamanca, Spain
Minnema, MC:
UMC Utrecht Canc Ctr, Utrecht, Netherlands
Costa, L:
Univ Alabama Birmingham, Birmingham, AL USA
Verona, R:
Janssen R&D, Spring House, PA USA
Girgis, S:
Janssen R&D, Spring House, PA USA
Prior, T:
Janssen R&D, Spring House, PA USA
Hilder, B:
Janssen R&D, Spring House, PA USA
Russell, J:
Janssen R&D, Spring House, PA USA
Goldberg, J:
Janssen R&D, Raritan, NJ USA
Chari, A:
Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA
|